State of Tennessee Treasury Department lessened its position in shares of Cambrex Co. (NYSE:CBM) by 9.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 25,624 shares of the biotechnology company’s stock after selling 2,790 shares during the period. State of Tennessee Treasury Department’s holdings in Cambrex were worth $1,230,000 at the end of the most recent reporting period.
Other hedge funds have also recently bought and sold shares of the company. Visionary Asset Management Inc. purchased a new stake in Cambrex during the third quarter valued at about $201,000. Trexquant Investment LP purchased a new stake in Cambrex during the third quarter valued at about $209,000. Advisor Group Inc. grew its position in Cambrex by 52.9% during the third quarter. Advisor Group Inc. now owns 4,100 shares of the biotechnology company’s stock valued at $226,000 after acquiring an additional 1,419 shares during the period. Sei Investments Co. grew its position in Cambrex by 3,120.9% during the third quarter. Sei Investments Co. now owns 4,155 shares of the biotechnology company’s stock valued at $228,000 after acquiring an additional 4,026 shares during the period. Finally, Highbridge Capital Management LLC purchased a new stake in shares of Cambrex in the third quarter worth about $238,000.
Shares of Cambrex Co. (NYSE:CBM) opened at $55.10 on Monday. Cambrex Co. has a 1 year low of $42.55 and a 1 year high of $62.95. The firm has a market capitalization of $1,809.86, a PE ratio of 16.90, a PEG ratio of 1.33 and a beta of 2.38.
Several equities research analysts have recently weighed in on CBM shares. William Blair started coverage on Cambrex in a research report on Tuesday, January 16th. They issued an “outperform” rating for the company. Zacks Investment Research raised Cambrex from a “strong sell” rating to a “hold” rating in a research report on Monday, January 15th. Finally, Longbow Research downgraded Cambrex from a “buy” rating to a “neutral” rating in a research report on Wednesday, February 14th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and two have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus target price of $60.00.
Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc, Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l.
Want to see what other hedge funds are holding CBM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cambrex Co. (NYSE:CBM).
Receive News & Ratings for Cambrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex and related companies with MarketBeat.com's FREE daily email newsletter.